Use of Escherichia coli Nissle 1917 producing recombinant colicins for treatment of IBD patients.

Abstract

Patients with Crohn's Disease and Ulcerative Colitis infected with Adherent-Invasive Escherichia coli strains constitute the largest group among Inflammatory Bowel Disease subjects, when taking into account all known etiological agents of the disease. A possible link between these pathogenic bacteria and inflammation process has gained the confidence in recently published papers. Observed enteric neuroglial cells apoptosis and epithelial gaps of ileum are probably the key manifestations of inflammation, which has been shown in IBD patients in contrary to the samples taken from healthy individuals. The cascade of consecutive events from bacterial infection via inflammation to excessive apoptosis in IBD patients leads up to the aim of our hypothesis about designing of new therapeutic strategy directed to Adherent-Invasive E. coli strains. The main advantage of biological method, which will rely on application of E. coli Nissle 1917 strain as a carrier for specific recombinant colicins against AIEC strains, could probably cause a long-lasting remission of inflammation in CD and UC patients.

• Authors: Roman Kotłowski
• Journal: Medical hypotheses (Med Hypotheses) Vol. 93 Pg. 8-10 (Aug 2016) ISSN: 1532-2777 [Electronic] United States
• PMID: 27372848 (Publication Type: Journal Article)
• Copyright: Copyright © 2016 Elsevier Ltd. All rights reserved.

Chemical References

• Anti-Bacterial Agents
• Colicins
• Recombinant Proteins

Topics

• Animals
• Anti-Bacterial Agents (therapeutic use)
• Apoptosis
• Colicins (biosynthesis, therapeutic use)
• Colitis, Ulcerative (microbiology, therapy)
• Crohn Disease (microbiology, therapy)
• Escherichia coli (metabolism, pathogenicity)
• Humans
• Inflammation
• Intestinal Mucosa (metabolism)
• Macrophages (metabolism)
• Models, Theoretical
• Recombinant Proteins (biosynthesis, therapeutic use)
• Remission Induction